Physician profile
Stephen H Lin
NPI 1063688117
$1,100.68
in general payments reported to CMS, 2019-2025
24 companies · $59.31 in 2025
The $59.31 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $148 · 2021: $128 · 2022: $175 · 2023: $78.62 · 2024: $211 · 2025: $59.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $256 · Travel and Lodging: $93.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $255.53 |
| Travel and Lodging | $93.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $203.10 | 2019 | |
| Intuitive Surgical, INC. | $188.58 | 2019-2024 | |
| Bausch & Lomb Americas INC. | $107.93 | 2022 | |
| Medtronic, INC. | $103.45 | 2021-2025 | Interstim, Progrip |
| Stryker Corporation | $69.36 | 2020-2023 | Pinpoint |
| Smith+Nephew, INC. | $47.51 | 2022-2024 | Collagenase Santyl |
| Abbvie INC. | $45.73 | 2024 | |
| Acell, INC. | $34.67 | 2020 | |
| Kerecis Limited | $30.23 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Davol INC. | $27.98 | 2020 | |
| Abbott Laboratories | $24.55 | 2023 | Proclaim |
| Takeda Pharmaceuticals U.S.A., INC. | $22.17 | 2021 | |
| Merck Sharp & Dohme LLC | $19.45 | 2025 | Zerbaxa |
| Axonics, INC. | $19.07 | 2021 | |
| Baxter Healthcare | $18.68 | 2024 | Tisseel |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rti Surgical, INC | $18.50 | 2022 | |
| Innocoll Pharmaceuticals Limited | $17.88 | 2022 | |
| Tela Bio, INC. | $16.79 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Solventum Corporation | $15.94 | 2024 | Activ.A.C., Promogran Prisma |
| Novo Nordisk INC | $15.32 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.22 | 2020 | |
| Grifols USA, LLC | $13.57 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $13.02 | 2021 | |
| Braintree Laboratories, INC. | $12.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.